<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Mesalazine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00244</strong>&#160; (APRD01098)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An anti-inflammatory agent, structurally related to the salicylates, which is active in inflammatory bowel disease. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00244/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00244/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00244.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00244.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00244.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00244.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00244.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00244">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>3-carboxy-4-hydroxyaniline</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-aminosalicylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-ASA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>m-Aminosalicylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mesalamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>APRISO</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Asacol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Asacolitin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Canasa</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Claversal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Delzicol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Fisalamine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lixacol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mesasal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pentasa</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rowasa</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Salofalk</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li></ul></td></tr><tr><th>CAS number</th><td>89-57-6</td></tr><tr><th>Weight</th><td>Average: 153.1354<br>Monoisotopic: 153.042593095</td></tr><tr><th>Chemical Formula</th><td>C<sub>7</sub>H<sub>7</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>KBOPZPXVLCULAV-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-amino-2-hydroxybenzoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=CC(C(O)=O)=C(O)C=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00244.gif?1265922773">show</a>(8.48 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzoic Acid and Derivatives</td></tr><tr><th>Direct parent</th><td>Aminobenzoic Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Salicylic Acids; Benzoic Acids; Benzoyl Derivatives; Aminophenols; Anilines; Primary Aromatic Amines; Polyols; Enols; Carboxylic Acids; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>aminophenol; benzoyl; phenol derivative; aniline; primary aromatic amine; polyol; polyamine; carboxylic acid derivative; enol; carboxylic acid; enolate; amine; primary amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminobenzoic acid derivatives. These are benzoic acids (or derivative thereof) containing an amine group attached to the benzene moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of active ulcerative proctitis.</td></tr><tr><th>Pharmacodynamics</th><td>Mesalazine (INN, BAN), also known as Mesalamine (USAN) or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism.</td></tr><tr><th>Mechanism of action</th><td>Although the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.</td></tr><tr><th>Absorption</th><td>20 to 30% absorbed following oral administration. 10 to 35% absorbed from the colon (rectal suppository) - extent of absorption is determined by the length of time the drug is retained in the colon.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>About 80% of N-Ac-5-ASA is bound to plasma proteins, whereas 40% of mesalamine is protein bound.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Rapidly and extensively metabolized, mainly to N-acetyl-5-ASA (Ac-5-ASA) in the intestinal mucosal wall and the liver. Ac-5-ASA is further acetylated (deactivated) in at least 2 sites, the colonic epithelium and the liver.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Mesalazine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00924">N-acetyl-5-ASA (Ac-5-ASA)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/945">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Approximately 28% of the mesalamine in Asacol tablets is absorbed after oral ingestion, leaving the remainder available for topical action and excretion in the feces.
It is excreted mainly by the kidney as N-acetyl-5-aminosalicylic acid.</td></tr><tr><th>Half life</th><td>The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 3370 mg/kg; Oral, rat: LD<sub>50</sub> = 2800 mg/kg; Skin, rabbit: LD<sub>50</sub> = &gt;5 gm/kg. There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalazine absorption from the colon is limited.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9471</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.6168</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8829</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8186</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.985</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9912</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9314</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8284</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8331</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7636</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8712</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9744</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.6752</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6628</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9023</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7922
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.6197
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.7065 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9759
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9715
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Salix pharmaceuticals inc</li>
<li>Shire development inc</li>
<li>Perrigo israel pharmaceuticals ltd</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Alaven pharmaceutical llc</li>
<li>Axcan pharma us inc</li>
<li>Warner chilcott pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.alavenpharm.com">Alaven Pharmaceutical</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Anip Acquisition Co.</li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.axcan.com">Axcan Pharma Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Cosmo SPA</li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.ferring.com">Ferring Pharmaceuticals Inc.</a></li>
<li>Franklin Pharmaceutical LLC</li>
<li><a href="http://www.gavispharma.com">Gavis Pharmaceuticals LLC</a></li>
<li>Heartland Repack Services LLC</li>
<li>Infar SA</li>
<li><a href="http://www.letcomedical.com">Letco Medical Inc.</a></li>
<li><a href="http://www.norwichpharma.com">Norwich Pharmaceuticals Inc.</a></li>
<li><a href="http://www.paddocklabs.com">Paddock Labs</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.perrigo.com">Perrigo Co.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prasco.com">Prasco Labs</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.salix.com">Salix Pharmaceuticals</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li><a href="http://www.shire.com">Shire Inc.</a></li>
<li><a href="http://global.abbottgrowth.com">Solvay Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://ir.wcrx.com">Warner Chilcott Co. Inc.</a></li>
<li>WC Pharmaceuticals</li>
<li><a href="http://www.wellspringpharm.com">Wellspring Pharmaceutical</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Enema</td><td>Rectal</td><td></td></tr><tr><td>Suppository</td><td>Rectal</td><td></td></tr><tr><td>Suspension</td><td>Rectal</td><td></td></tr><tr><td>Tablet, coated</td><td>Oral</td><td></td></tr><tr><td>Tablet, delayed release</td><td>Oral</td><td></td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00993">Azathioprine</a></td><td>Mesalazine may increase the toxicity of thiopurine, azathioprine.</td></tr><tr><td><a href="/drugs/DB01033">Mercaptopurine</a></td><td>Mesalazine may increase the toxicity of thiopurine, mercaptopurine.</td></tr><tr><td><a href="/drugs/DB00352">Tioguanine</a></td><td>Mesalazine may increase the toxicity of thiopurine, thioguanine.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>